IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:	**ISPH-0798**
Inventors:	**Murray and Wyatt**
Serial No.:	**Not Yet Assigned**
Filing Date:	**Herewith**
Examiner:	**Not Yet Assigned**
Group Art Unit:	**Not Yet Assigned**
Title:	**Antisense Modulation of Transforming Growth Factor Beta Receptor II Expression**

"Express Mail" Label No. **EV402354815US**
Date of Deposit **November 10, 2003**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Sequence, P. O. Box 1450, Alexandria, VA 22313-1450.

By _____
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

( ) The fee of $**180.00** as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of $**130.00** as set forth in §1.17(I)(1).

( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. **09/888,361** filed **June 21, 2001** for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata
Registration No. 32,257

Date: **November 10, 2003**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

DOCKET NO.: ISPH-0798

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0798	Serial No. not yet assigned
	Applicant Susan Murray *et al.*	
	Filing Date herewith	Group not yet assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Bonyadi *et al.*, *The TGF beta type II receptor, Tgfbr2, maps to distal mouse chromosome 9*, *Genomics*, 1996, *33*:328-329
	AB	Chai *et al.*, *Inhibition of transforming growth factor-beta type II receptor signaling accelerates tooth formation in mouse first branchial arch explants*, *Mech. Dev.*, 1999, *86*:63-74
	AC	Hahm *et al.*, *Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein*, *Nat Genet*, 1999, *23*:222-227.
	AD	Hata, *TGFbeta signaling and cancer*, *Exp. Cell Res.*, 2001, *264*:111-116
	AE	Higashiyama *et al.*, *Inhibition by transforming growth factor-beta1 of the cellular action of arginine vasopressin in cultured rat glomerular mesangial cells*, *Hypertens. Res.*, 1999, *22*:173-180
	AF	Imai *et al.*, *Gene transfer and kidney disease*, *J. Nephrol.*, 1998, *11*:16-19
	AG	Lin *et al.*, *Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase*, *Cell*, 1992, *68*:775-785
	AH	Liu *et al.*, *Transforming growth factor beta2, but not beta1 and beta3, is critical for early rat lung branching*, *Dev. Dyn.*, 2000, *217*:343-360
	AI	Lucke *et al.*, *Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer*, *Cancer Res.*, 2001, *61*:482-485
	AJ	Markowitz *et al.*, *Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability*, *Science*, 1995, *268*:1336-1338
	AK	Markowitz, *Atherosclerosis, just another cancer?*, *J. Clin. Invest.*, 1997, *100*:2143-2145
	AL	Mathew *et al.*, *Transforming growth factor receptor gene TGFBR2 maps to human chromosome band 3p22*, *Genomics*, 1994, *20*:114-115

EXAMINER	DATE CONSIDERED

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0798	Serial No. not yet assigned
	Applicant Susan Murray *et al.*	
	Filing Date herewith	Group not yet assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AM	McCaffrey *et al.*, *The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance, J. Mol. Cell Cardiol.*, 1999, *31*:1627-1642
	AN	Oshima *et al.*, *TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis, Dev. Biol.*, 1996, *179*:297-302
	AO	Pasche, *Role of transforming growth factor beta in cancer, J. Cell Physiol.*, 2001, *186*:153-168
	AP	Piek *et al.*, *Specificity, diversity, and regulation in TGF-beta superfamily signaling, Faseb J.*, 1999, *13*:2105-2124
	AQ	Rotzer *et al.*, *Type III TGF-.beta. receptor-independent signalling of TGF-.beta.2 via T.beta.RII-B, an alternatively spliced TGF-.beta. type II receptor, Embo J.*, 2001, *20*:480-490
	AR	Shah *et al.*, *TGF-beta-based immunotherapy for cancer: breaching the tumor firewall, Prostate*, 2000, *45*:167-172
	AS	Venkatasubbarao *et al.*, *Novel mutations in the polyadenine tract of the transforming growth factor beta type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas, Genes Chromosomes Cancer*, 1998, *22*:138-144
	AT	Yu *et al.*, *Evidence for role of transforming growth factor-beta in RRR-alpha-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells, Nutr. Cancer*, 1997, *27*:267-278
	AU	Zhao *et al.*, *Abrogation of transforming growth factor-beta type II receptor stimulates embryonic mouse lung branching morphogenesis in culture, Dev. Biol.*, 1996, *180*:242-257

EXAMINER	DATE CONSIDERED

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0798	Serial No. not yet assigned
	Applicant Susan Murray et al.	
	Filing Date herewith	Group not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA	6,008,011	12/28/1999	Lin *et al.*	435	69.1
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES	Translation NO
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

EXAMINER	DATE CONSIDERED